Mirikizumab for previously treated moderately to severely active Crohn's disease

Mirikizumab can be used as an option to treat moderately to severely active Crohn's disease in adults, only if:

• the disease has not responded well enough or stopped responding to a previous biological treatment, or
• a previous biological treatment was not tolerated, or
• tumour necrosis factor (TNF)-alpha inhibitors are not suitable.

Mirikizumab can only be used if the company provides it according to the commercial arrangement.

If people with the condition and their healthcare professional consider mirikizumab to be 1 of a range of suitable treatments, after discussing the advantages and disadvantages of all the options, the least expensive should be used. Take into account the administration costs, dosage, price per dose and commercial arrangements.

We expect the resource impact of implementing the recommendations in England will be less than £5 million per year (or approximately £8,800 per 100,000 population, based on a population for England of 57.1 million people).

This is because the technology is a further treatment option and the overall cost of treatment will be similar for this patient group.

More detail will be provided in an upcoming resource impact summary report and resource impact template for this topic.

The company has a commercial arrangement. This makes mirikizumab available to the NHS with a discount. The size of the discount is commercial in confidence.

This technology is commissioned by integrated care boards. Providers are NHS hospital trusts.

The payment mechanism for the technology is determined by the responsible commissioner and depends on the technology being classified as high cost.